Tumor Biology

, Volume 37, Issue 5, pp 6323–6330 | Cite as

Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis

  • Xiangrong Liu
  • Jun Kang
  • Fang Liu
  • Shaohong Wen
  • Xianwei Zeng
  • Kuan Liu
  • Yumin Luo
  • Xunming Ji
  • Shangfeng Zhao
Original Article


Inhibitor of apoptosis-stimulating protein of p53 (iASPP), encoded by PPP1R13L gene, is often overexpressed in human cancers. From the PPP1R13L gene, at least two isoforms, iASPP-L and iASPP-SV, are produced through alternative splicing. However, the role of these isoforms in glioma is still elusive. In this study, we examined the expression of iASPP-SV in astrocytic glioma tissues with different grades and normal human cerebral tissues. The result showed a higher messenger RNA (mRNA) expression level of iASPP-SV in astrocytic glioma patients with World Health Organization (WHO) grade II to IV in comparison to the normal controls. Additionally, mRNA expression level of iASPP-SV was gradually increased with the raise of the grade in glioma. High mRNA expression level of iASPP-SV was significantly associated with malignant WHO grades (P < 0.001). The protein expression level of iASPP-SV was consistent with the mRNA expression level. The Kaplan–Meier analysis revealed that high iASPP-SV mRNA expression significantly affected overall survival and progression-free survival (both P < 0.001). Furthermore, multivariate analysis indicated that the mRNA expression of iASPP-SV was an independent prognostic marker in glioma (P < 0.001). To further explore the role of iASPP-SV in glioma, U87 cells were transfected with iASPP-SV by lentivirus and then treated with temozolomide (TMZ). Overexpression of iASPP-SV promoted the cell viability and downregulated the expression of pro-apoptosis genes (Bax, Puma, p21, and Noxa) to inhibit apoptosis induced by TMZ. Our study provides the first evidence that high iASPP-SV expression may be a novel prognostic factor and therapeutic target for glioma.


Isoform iASPP Glioma Prognosis Survival Apoptosis 



We thank Prof. Jianxiang Wang (Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College) for providing pCDH-iASPPsv plasmid and the packing plasmids. We thank Lei Wang (Beijing Tiantan Hospital, Capital Medical University), Zhaoke Zheng, and Kaiyuan Song (Beijing Tongren Hospital, Capital Medical University) for collecting some part of tissue samples. This work was supported by the National Natural Science Foundation of China (grant nos. 81000504, 81471209, 81171241), the Beijing Natural Science Foundation (grant no. 7132112), and Special Research Projects in Public Health and Welfare of China (grant no. 20142008-10).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Rousseau A, Mokhtari K, Duyckaerts C. The 2007 WHO classification of tumors of the central nervous system—what has changed? Curr Opin Neurol. 2008;21:720–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Snape TJ, Warr T. Approaches toward improving the prognosis of pediatric patients with glioma: pursuing mutant drug targets with emerging small molecules. Semin Pediatr Neurol. 2015;22:28–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang F, Xu CL, Liu CM. Drug delivery strategies to enhance the permeability of the blood–brain barrier for treatment of glioma. Drug Des Devel Ther. 2015;9:2089–100.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yang QY, Guo CC, Chen ZP. Profile of nimotuzumab in the treatment of high-grade glioma. Oncol Targets Ther. 2015;8:819–25.Google Scholar
  6. 6.
    Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.CrossRefPubMedGoogle Scholar
  7. 7.
    Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16:iv1–63.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003;33:162–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol. 2004;24:1341–50.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer. 2006;6:217–26.CrossRefPubMedGoogle Scholar
  11. 11.
    Bell HS, Ryan KM. iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res. 2008;68:4959–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer. 2007;96:196–200.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res. 2005;29:179–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu Z, Zhang X, Huang D, Liu Y, Zhang X, Liu L, et al. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Med Oncol. 2012;29:3381–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Cao L, Huang Q, He J, Lu J, Xiong Y. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2013;352:361–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang X, Diao S, Rao Q, Xing H, Liu H, Liao X, et al. Identification of a novel isoform of iASPP and its interaction with p53. J Mol Biol. 2007;368:1162–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang L, Xing H, Tian Z, Peng L, Li Y, Tang K, et al. iASPPsv antagonizes apoptosis induced by chemotherapeutic agents in MCF-7 cells and mouse thymocytes. Biochem Biophys Res Commun. 2012;424:414–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang JW, Wan XY, Zhu HT, Lu C, Yu WL, Yu CH, et al. Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells. PLoS ONE. 2014;9, e96124.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, et al. MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke. 2013;44:1973–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu X, Zhang Q, Zhang DE, Zhou C, Xing H, Tian Z, et al. Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. Leukemia. 2009;23:739–45.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang WB, Wang Z, Shu F, Jin YH, Liu HY, Wang QJ, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem. 2010;285:40461–71.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.CrossRefGoogle Scholar
  24. 24.
    Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Inoue K, Fry EA. Alterations of p63 and p73 in human cancers. Subcell Biochem. 2014;85:17–40.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cai Y, Qiu S, Gao X, Gu SZ, Liu ZJ. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis. 2012;17:777–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Woodard C, Liao G, Goodwin CR, Hu J, Xie Z, Dos Reis TF, et al. A screen for extracellular signal-regulated kinase-primed glycogen synthase kinase 3 substrates identifies the p53 inhibitor iASPP. J Virol. 2015;89:9232–41.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lin BL, Xie DY, Xie SB, Xie JQ, Zhang XH, Zhang YF, et al. Down-regulation of iASPP in human hepatocellular carcinoma cells inhibits cell proliferation and tumor growth. Neoplasma. 2011;58:205–10.CrossRefPubMedGoogle Scholar
  29. 29.
    Li G, Wang R, Gao J, Deng K, Wei J, Wei Y. RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells. Mol Cell Biochem. 2011;350:193–200.CrossRefPubMedGoogle Scholar
  30. 30.
    Liu ZJ, Cai Y, Hou L, Gao X, Xin HM, Lu X, et al. Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest. 2008;26:878–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Morris EV, Cerundolo L, Lu M, Verrill C, Fritzsche F, White MJ, et al. Nuclear iASPP may facilitate prostate cancer progression. Cell Death Dis. 2014;5, e1492.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kramer D, Schön M, Bayerlová M, Bleckmann A, Schön MP, Zörnig M, et al. A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity. Cell Death Dis. 2015;6, e1634.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Cerebrovascular Diseases Research InstituteXuanwu Hospital of Capital Medical UniversityBeijingChina
  2. 2.Key Laboratory of Neurodegenerative Diseases, Ministry of EducationCapital Medical UniversityBeijingChina
  3. 3.Department of Neurosurgery, Beijing Tongren HospitalCapital Medical UniversityBeijingChina
  4. 4.Department of NeurosurgeryThe Affiliated Hospital of Weifang Medical CollegeWeifangChina

Personalised recommendations